Rosa Maria Laterza
No ORCID on file
· 2 papers in corpus
· active 2014-2022
Study types
- article 2
Condition tags
- dysmenorrhea 1
- endometriosis 1
Top journals
Frequent coauthors
article
2022
article
2014
STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…